$270 Million is the total value of Casdin Capital, LLC's 35 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 41.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LOXO | LOXO ONCOLOGY INC | $28,868,000 | +90.6% | 360,000 | 0.0% | 10.68% | +19.5% | |
| SAGE | SAGE THERAPEUTICS INC | $20,308,000 | +12.1% | 255,000 | 0.0% | 7.51% | -29.7% | |
| FMI | FOUNDATION MEDICINE INC | $19,080,000 | +23.3% | 480,000 | 0.0% | 7.06% | -22.7% | |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $13,934,000 | +18.3% | 275,000 | -6.6% | 5.15% | -25.8% |
| EVH | EVOLENT HEALTH INCcl a | $13,182,000 | +13.7% | 520,000 | 0.0% | 4.88% | -28.7% | |
| AGIO | Buy | AGIOS PHARMACEUTICALS INC | $13,120,000 | -5.4% | 255,000 | +7.4% | 4.85% | -40.7% |
| SGMO | Buy | SANGAMO THERAPEUTICS INC | $12,320,000 | +178.7% | 1,400,000 | +64.7% | 4.56% | +74.8% |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $12,172,000 | +731.4% | 130,000 | +465.2% | 4.50% | +421.1% |
| XBI | New | SPDR SERIES TRUSTput | $11,577,000 | – | 150,000 | +100.0% | 4.28% | – |
| ONCE | Buy | SPARK THERAPEUTICS INC | $10,156,000 | +41.0% | 170,000 | +25.9% | 3.76% | -11.6% |
| KITE | Buy | KITE PHARMA INC | $9,330,000 | +179.7% | 90,000 | +111.8% | 3.45% | +75.4% |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $8,375,000 | +197.1% | 105,000 | +90.9% | 3.10% | +86.3% |
| GNMK | Buy | GENMARK DIAGNOSTICS INC | $8,104,000 | +58.0% | 685,000 | +71.2% | 3.00% | -0.9% |
| EPZM | Buy | EPIZYME INC | $7,852,000 | -5.6% | 520,000 | +7.2% | 2.90% | -40.8% |
| BOLD | Buy | AUDENTES THERAPEUTICS INC | $7,652,000 | +72.7% | 400,000 | +53.8% | 2.83% | +8.3% |
| BLUE | Buy | BLUEBIRD BIO INC | $6,828,000 | +194.6% | 65,000 | +154.9% | 2.53% | +84.8% |
| TSRO | Buy | TESARO INC | $6,713,000 | +149.3% | 48,000 | +174.3% | 2.48% | +56.3% |
| VYGR | Buy | VOYAGER THERAPEUTICS INC | $6,630,000 | +0.2% | 740,000 | +48.0% | 2.45% | -37.2% |
| CDXS | Buy | CODEXIS INC | $6,486,000 | +100.2% | 1,190,000 | +76.3% | 2.40% | +25.5% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $5,880,000 | +57.2% | 215,000 | +111.8% | 2.18% | -1.4% |
| ILMN | New | ILLUMINA INC | $5,466,000 | – | 31,500 | +100.0% | 2.02% | – |
| GILD | New | GILEAD SCIENCES INC | $5,309,000 | – | 75,000 | +100.0% | 1.96% | – |
| MYOK | Buy | MYOKARDIA INC | $5,175,000 | +48.5% | 395,000 | +49.1% | 1.91% | -6.9% |
| GILD | New | GILEAD SCIENCES INCcall | $4,247,000 | – | 60,000 | +100.0% | 1.57% | – |
| SYRS | SYROS PHARMACEUTICALS INC | $2,931,000 | +1.0% | 182,141 | 0.0% | 1.08% | -36.7% | |
| CTMX | CYTOMX THERAPEUTICS INC | $2,751,000 | -10.2% | 177,500 | 0.0% | 1.02% | -43.7% | |
| MYGN | New | MYRIAD GENETICS INCcall | $2,584,000 | – | 100,000 | +100.0% | 0.96% | – |
| OVID | New | OVID THERAPEUTICS INC | $2,326,000 | – | 221,700 | +100.0% | 0.86% | – |
| JNCE | Buy | JOUNCE THERAPEUTICS INC | $2,245,000 | -21.5% | 160,000 | +23.1% | 0.83% | -50.8% |
| EDIT | EDITAS MEDICINE INC | $2,237,000 | -24.8% | 133,333 | 0.0% | 0.83% | -52.9% | |
| MDRX | New | ALLSCRIPTS HEALTHCARE SOLUTNcall | $1,914,000 | – | 150,000 | +100.0% | 0.71% | – |
| FATE | New | FATE THERAPEUTICS INC | $1,782,000 | – | 550,000 | +100.0% | 0.66% | – |
| AMRS | New | AMYRIS INC | $1,590,000 | – | 500,000 | +100.0% | 0.59% | – |
| PACB | Sell | PACIFIC BIOSCIENCES CALIF IN | $1,068,000 | -70.5% | 300,000 | -57.1% | 0.40% | -81.5% |
| CRIS | Sell | CURIS INC | $161,000 | -74.8% | 85,000 | -63.0% | 0.06% | -84.1% |
| ADVM | Exit | ADVERUM BIOTECHNOLOGIES INC | $0 | – | -420,000 | -100.0% | -0.67% | – |
| AMRS | Exit | AMYRIS INC | $0 | – | -6,000,000 | -100.0% | -1.88% | – |
| MDRX | Exit | ALLSCRIPTS HEALTHCARE SOLUTN | $0 | – | -310,000 | -100.0% | -2.32% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
| 13F-HR | 2024-02-14 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.